PharmaSGP Holding SE (PSG) - Total Assets
Based on the latest financial reports, PharmaSGP Holding SE (PSG) holds total assets worth €118.18 Million EUR (≈ $138.16 Million USD) as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See PharmaSGP Holding SE (PSG) shareholders funds for net asset value and shareholders' equity analysis.
PharmaSGP Holding SE - Total Assets Trend (2014–2024)
This chart illustrates how PharmaSGP Holding SE's total assets have evolved over time, based on quarterly financial data.
PharmaSGP Holding SE - Asset Composition Analysis
Current Asset Composition (December 2024)
PharmaSGP Holding SE's total assets of €118.18 Million consist of 47.0% current assets and 53.0% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 23.2% |
| Accounts Receivable | €13.20 Million | 11.6% |
| Inventory | €10.44 Million | 9.1% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €58.82 Million | 51.5% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how PharmaSGP Holding SE's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of PharmaSGP Holding SE.
Key Asset Composition Facts
- Current vs. Non-Current Assets: PharmaSGP Holding SE's current assets represent 47.0% of total assets in 2024, a decrease from 52.6% in 2014.
- Cash Position: Cash and equivalents constituted 23.2% of total assets in 2024, up from 13.1% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 51.0% of total assets, an increase from 19.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 51.5% of total assets.
PharmaSGP Holding SE Competitors by Total Assets
Key competitors of PharmaSGP Holding SE based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
| No similar companies found. | ||
PharmaSGP Holding SE - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.68 | 2.53 | 1.37 |
| Quick Ratio | 2.24 | 2.19 | 1.21 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €37.44 Million | €44.75 Million | €5.82 Million |
PharmaSGP Holding SE - Advanced Valuation Insights
This section examines the relationship between PharmaSGP Holding SE's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.04 |
| Latest Market Cap to Assets Ratio | 2.90 |
| Asset Growth Rate (YoY) | -13.0% |
| Total Assets | €114.27 Million |
| Market Capitalization | $331.56 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values PharmaSGP Holding SE's assets at a significant premium (2.90x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: PharmaSGP Holding SE's assets decreased by 13.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for PharmaSGP Holding SE (2014–2024)
The table below shows the annual total assets of PharmaSGP Holding SE from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €114.27 Million ≈ $133.60 Million |
-12.97% |
| 2023-12-31 | €131.30 Million ≈ $153.50 Million |
+1.70% |
| 2022-12-31 | €129.11 Million ≈ $150.94 Million |
+12.02% |
| 2021-12-31 | €115.26 Million ≈ $134.75 Million |
+362.07% |
| 2020-12-31 | €24.94 Million ≈ $29.16 Million |
-75.96% |
| 2019-12-31 | €103.74 Million ≈ $121.28 Million |
+24.39% |
| 2017-12-31 | €83.40 Million ≈ $97.51 Million |
+4.26% |
| 2016-12-31 | €80.00 Million ≈ $93.53 Million |
+3.57% |
| 2015-12-31 | €77.24 Million ≈ $90.31 Million |
+12.94% |
| 2014-12-31 | €68.39 Million ≈ $79.96 Million |
-- |
About PharmaSGP Holding SE
PharmaSGP Holding SE manufactures and sells over-the-counter drugs and other healthcare products in Germany. The company's pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage creams for the treatment of various pain conditions; RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil … Read more